CN101732334A - Composition for preventing and treating cerebral ischemic apoplexy - Google Patents
Composition for preventing and treating cerebral ischemic apoplexy Download PDFInfo
- Publication number
- CN101732334A CN101732334A CN200810171801A CN200810171801A CN101732334A CN 101732334 A CN101732334 A CN 101732334A CN 200810171801 A CN200810171801 A CN 200810171801A CN 200810171801 A CN200810171801 A CN 200810171801A CN 101732334 A CN101732334 A CN 101732334A
- Authority
- CN
- China
- Prior art keywords
- parts
- acid
- ingredient
- jasminoidin
- baicalin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition for preventing and treating cerebral ischemic apoplexy. The composition comprises the following components according to parts by weight: 5-30 parts of cholic acid, 10-20 parts of deoxycholic acid, 1-10 parts of jasminoidin and 5-30 parts of baicalin; the composition is added with pharmaceutically acceptable auxiliary materials and is an oral preparation, an injection preparation and an externally-applied paste prepared according to the technical requirement of the pharmaceutical pharmacy. The composition has obvious curative effect for preventing and treating cerebral ischemic apoplexy.
Description
Technical field
The present invention relates to the compositions of a kind of prevention and treatment cerebral infarction.
Background technology
Apoplexy is commonly encountered diseases, the frequently-occurring disease of middle-aged and elderly people, be one of three the highest big diseases of human now mortality rate, also be with fastest developing speed in the three big diseases, recover the slowest, the dead disease kind that at most, disables the heaviest, cause very big misery to the mankind, bring serious harm for family and society.Along with aged tendency of population, the stroke onset rate is in rising trend, and the data according to WHO announces in 57 countries, has 40 countries that the mortality rate of apoplexy has been listed in the 3rd, has wherein accounted for the first place in Japan and China.In all paralytics, cerebral infarction (ischemic stroke) accounts for 70-80%, therefore, develops new medicine to reduce its mortality rate and disability rate, is important topic and tackling key problem emphasis that this field medical investigator faces always.The invention provides a kind of compositions for the treatment of cerebral infarction.
Summary of the invention
Chinese medicine is by intravenous injection or administered intramuscular, has rapid-action and advantage such as determined curative effect, is the main kind of present clinical application.2004-2006 Chinese medicine clinical application sales volume, preceding 3 kind of rank is Chinese medicine entirely, has 7 to be injection (comprising the injection Chinese medicine preparation) in preceding 10 medicine of rank.Particularly treat the Chinese medicine of cardiovascular and cerebrovascular disease, because original effect is arranged, clinical use amount even can contend with the Western medicine product.Based on good economic and social benefit, Chinese medicine also is the focus of research and development always, and the Chinese medicine of existing national standard has reached 105 at present.
But along with Chinese medicine clinical application amount is soaring year by year, adverse reaction rate also improves thereupon.In 780 piece of 3009 routine adverse reaction of tcm report of 1960-1993, what injection caused only accounts for 6.3%; In 460 piece of 1291 routine adverse reaction of tcm report of 1990-1999, what injection caused accounted for 56%, accounted for nearly 70-80% to 2005.Therefore, the safety issue of Chinese medicine has become the great strategic issue that current China need solve.
QINKAILING ZHUSHEYE (QKL) is that Beijing University of Chinese Medicine in 1974 forms according to the cow-bezoar bolus for resurrection side of tearing open the transformation of the way in " Wenbing Tiaobian, Detailed Analysis of Epidemic Warm Diseases "; be mainly used in the treatment of viral influenza at first; the scope of application was constantly expanded afterwards; be used for the treatment of multiple acute and chronic diseases at present; particularly to be applied to brains such as acute ischemic stroke be disease to QINKAILING ZHUSHEYE; have definite curative effect, demonstrate the unique advantage of Chinese medicine.Since 1992, continuous three times is the first-selected required medicines of national hospital of traditional Chinese hospital emergency treatment by authorization, is the first-selected Chinese patent medicine of acute apoplexy.Along with the scope of application is constantly expanded, the caused untoward reaction case of QKL also day by day increases, wherein based on the I allergic reaction type, the form of expression is varied, comprises respiratory response (as asthma, acute laryngeal obstruction, acute lung edema), anaphylactic shock, allergic dermatitis etc.For this reason, in that QINGKAILING treatment cerebral ischemia mechanism and effective ingredient are carried out on the basis of systematic study, the present invention proposes a kind of compositions for the treatment of cerebral ischemia.
The parts by weight of this pharmaceutical composition are: cholic acid 5-30 part Hyodeoxycholic Acid 10-20 part jasminoidin 1-10 part baicalin 5-30 part.
Be preferably: cholic acid 5-20 part, Hyodeoxycholic Acid 10-15 part, jasminoidin 2-8 part, baicalin 10-25 part.
More preferably: 20 parts of 5 parts of baicalins of 10 parts of jasminoidins of 15 parts of Hyodeoxycholic Acid of cholic acid.
The cholic acid of this pharmaceutical composition, Hyodeoxycholic Acid, jasminoidin and content of baicalin are 95-98%.
Above-mentioned arbitrary compositions, this pharmaceutical composition adds pharmacy acceptable auxiliary, oral formulations, ejection preparation and the external use plaster made according to the specification requirement of galenic pharmacy.Wherein oral formulations is selected from tablet, capsule, granule, pill, powder, drop pill, syrup, mixture, distillate medicinal water, or the sustained-release preparation of tablet, capsule, granule, pill, powder, drop pill.External use plaster is selected from crust cloth cream, rubber cream, black plaster.Ejection preparation is selected from intravenous injection, intramuscular dose, subcutaneous injection agent.
The present invention confirms that by pharmacodynamic experiment described Chinese medicine composition has the effect of significant prevention and treatment cerebral infarction.Concrete experimental technique is as follows:
(1) healthy adult Sprague Dawley male rat is 18, and body weight 250-300g is available from dimension tonneau China Experimental Animal Center.Rat is divided into 3 groups at random: sham operated rats (6), model group (6), this pharmaceutical composition group (6).
With reference to methods such as Zealonga, adopt improvement line bolt legal system to make the focal middle cerebral artery occlusion model of irritating again of rat.Chloral hydrate with 10% (3.5mL/kg) intraperitoneal injection of anesthesia rat, cervical region medisection is successively separated exposure right side external carotid artery, by the distal end ligation, proximal part is done otch and is inserted 2-0 fishing line (head end makes the spheroidal of the about 0.3mm of diameter with the chlorine silicone), inserts about 18-20mm, fishing line.The layer-by-layer suture otch, the fishing line stump is kept somewhere the about 5mm of otch outward.During ischemia 2h, fishing line extracted again pour into.Modeling successfully indicates: occur the hemiplegia that homonymy Horner levies, offside is attached most importance to forelimb after animal revives, draw circle to offside when creeping.
(2) this pharmaceutical composition group group, administration volume 0.1mL/10g, 2h before the art, postoperative 1h difference administration 1 time.Sham operated rats and model group give the normal saline of equivalent.After pouring into 24h again, broken end is got brain, and all capable coronal section of brain, cerebellum is drawn materials, and its deutocerebrum is being drawn materials for the center coronal section with the optic chiasma.The sham operated rats rat does not make ischemia and handles, and refuses Drug therapy yet, and the position of drawing materials is the same.
(3) function of nervous system's scoring: adopt the Bederson method,, carry out function of nervous system's scoring of limb function: 0 minute, do not have any neurological deficit respectively at irritating back 2h, 7h and 12h again; 1 minute, left fore flexing (it is positive promptly to propose the unsettled experiment of tail); 2 minutes, the thruster resistance descended (being that the lateral thrust experiment is positive), and companion's forelimb flexing does not have the behavior of turn-taking; 3 minutes, with 2 grades of behaviors, the spontaneous rotation of companion.
(4) the cerebral infarction stove is long-pending measures:
Open breast behind the model success 14h chloral hydrate intraperitoneal injection of anesthesia, through left ventricle perfusion normal saline 200ml, 4% paraformaldehyde 200ml, broken end is got brain, with full brain freezing 15min under-20 ℃, equidistantly cut 6 crown brain sheets backward continuously apart from volume 2mm, the thick 2mm of brain sheet inserts 2%TTC (2,3 immediately, 5 one triphenyltetrazolium chlorides) phosphate buffer (PBS, pH-7.4) in, 37 ℃ of lucifuge dyeing 30min, 4% paraformaldehyde solution is fixedly taken pictures behind the 24h.Adopt the multi-media color image analysis system to calculate section infarction kitchen range area, the long-pending V-S * D/T by formula of infarction stove.(S is each brain sheet infarction kitchen range area, and D is a brain sheet thickness, and T is the linear amplification multiple in calculating.
Experimental result shows that with respect to model group, described compositions can obviously reduce the thromboembolism volume of rat, can reduce 60-70%, alleviate the nervous function damage symptom, promptly there is obvious recovery in the rat function of nervous system of this pharmaceutical composition group behind 7h, by the 2-3 branch, drop to 1 fen or 0 minute.
Specific embodiment
Embodiment 1
Cholic acid 5g, Hyodeoxycholic Acid 10g, jasminoidin 1g, baicalin 5g dissolves in alkaline aqueous solution, after, transfer pH=7-9, filter, add the pharmacy acceptable auxiliary, according to the specification requirement of tablet on the galenic pharmacy, make the 1000ml injection altogether.Carry out zoopery by described pharmacodynamic experiment method, the result shows that this tablet has the Mus cerebral ischemia effect of the tangible Chinese People's Anti-Japanese Military and Political College.
Embodiment 2
Cholic acid 30g, Hyodeoxycholic Acid 20g, jasminoidin 10g, baicalin 30g dissolves in alkaline aqueous solution, after, transfer pH=7-9, filter, add the pharmacy acceptable auxiliary, according to the specification requirement of tablet on the galenic pharmacy, make the 1000ml injection altogether.Carry out zoopery by described pharmacodynamic experiment method, the result shows that this tablet has the Mus cerebral ischemia effect of the tangible Chinese People's Anti-Japanese Military and Political College.
Embodiment 3
Be preferably: cholic acid 5-20 part, Hyodeoxycholic Acid 10-15 part, jasminoidin 2-8 part, baicalin 10-25 part.
Cholic acid 5g, Hyodeoxycholic Acid 15g, jasminoidin 8g, baicalin 25g dissolves in alkaline aqueous solution, after, transfer pH=7-9, filter, add the pharmacy acceptable auxiliary, according to the specification requirement of tablet on the galenic pharmacy, make the 1000ml injection altogether.Carry out zoopery by described pharmacodynamic experiment method, the result shows that this tablet has the Mus cerebral ischemia effect of the tangible Chinese People's Anti-Japanese Military and Political College.
Embodiment 4
Cholic acid 20g, Hyodeoxycholic Acid 10g, jasminoidin 2g, baicalin 10g dissolves in alkaline aqueous solution, after, transfer pH=7-9, filter, add the pharmacy acceptable auxiliary, according to the specification requirement of tablet on the galenic pharmacy, make the 1000ml injection altogether.Carry out zoopery by described pharmacodynamic experiment method, the result shows that this tablet has the Mus cerebral ischemia effect of the tangible Chinese People's Anti-Japanese Military and Political College.
Embodiment 5
Cholic acid 30g, Hyodeoxycholic Acid 20g, jasminoidin 10g, baicalin 30g dissolves in alkaline aqueous solution, after, transfer pH=7-9, filter, add the pharmacy acceptable auxiliary, according to the specification requirement of tablet on the galenic pharmacy, make the 1000ml injection altogether.Carry out zoopery by described pharmacodynamic experiment method, the result shows that this tablet has the Mus cerebral ischemia effect of the tangible Chinese People's Anti-Japanese Military and Political College.
Embodiment 6
Cholic acid 1.5g, Hyodeoxycholic Acid 1g, jasminoidin 0.5g, baicalin 4g dissolves in alkaline aqueous solution, after, transfer pH=7-9, filter, add the pharmacy acceptable auxiliary, according to the specification requirement of tablet on the galenic pharmacy, make the 1000ml injection altogether.Carry out zoopery by described pharmacodynamic experiment method, the result shows that this tablet has the Mus cerebral ischemia effect of the tangible Chinese People's Anti-Japanese Military and Political College.
Claims (7)
1. the compositions of preventing and treating cerebral infarction is characterized in that the parts by weight of ingredient are: cholic acid 5-30 part Hyodeoxycholic Acid 10-20 part jasminoidin 1-10 part baicalin 5-30 part.
2. Chinese medicine composition according to claim 1 is characterized in that the ingredient parts by weight are: cholic acid 5-20 part Hyodeoxycholic Acid 10-15 part jasminoidin 2-8 part baicalin 10-25 part.
3. Chinese medicine composition according to claim 1 is characterized in that the ingredient parts by weight are: 20 parts of 5 parts of baicalins of 10 parts of jasminoidins of 15 parts of Hyodeoxycholic Acid of cholic acid.
4. according to the described arbitrary compositions of claim 1-3, it is characterized in that ingredient cholic acid, Hyodeoxycholic Acid, jasminoidin and content of baicalin are 95-98%.
5. according to the described arbitrary compositions of claim 1-3, this pharmaceutical composition adds pharmacy acceptable auxiliary, oral formulations, ejection preparation and the external use plaster made according to the specification requirement of galenic pharmacy.
6. compositions according to claim 5, it is characterized in that the oral formulations that this pharmaceutical composition is made is selected from tablet, capsule, granule, pill, powder, drop pill, syrup, mixture, distillate medicinal water, or the sustained-release preparation of tablet, capsule, granule, pill, powder, drop pill.External use plaster is selected from crust cloth cream, rubber cream, black plaster.
7. compositions according to claim 5 is characterized in that the ejection preparation that ingredient is made is selected from intravenous injection, intramuscular dose, subcutaneous injection agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810171801A CN101732334A (en) | 2008-11-13 | 2008-11-13 | Composition for preventing and treating cerebral ischemic apoplexy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810171801A CN101732334A (en) | 2008-11-13 | 2008-11-13 | Composition for preventing and treating cerebral ischemic apoplexy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101732334A true CN101732334A (en) | 2010-06-16 |
Family
ID=42456703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810171801A Pending CN101732334A (en) | 2008-11-13 | 2008-11-13 | Composition for preventing and treating cerebral ischemic apoplexy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101732334A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106914A (en) * | 2011-01-28 | 2011-06-29 | 康美药业股份有限公司 | Medicament for treating infectious diseases, preparation method and application thereof |
| CN104800234A (en) * | 2015-04-22 | 2015-07-29 | 张永胜 | Geniposide and baicalin medicinal composition |
-
2008
- 2008-11-13 CN CN200810171801A patent/CN101732334A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106914A (en) * | 2011-01-28 | 2011-06-29 | 康美药业股份有限公司 | Medicament for treating infectious diseases, preparation method and application thereof |
| CN102106914B (en) * | 2011-01-28 | 2012-09-05 | 康美药业股份有限公司 | Medicament for treating infectious diseases, preparation method and application thereof |
| CN104800234A (en) * | 2015-04-22 | 2015-07-29 | 张永胜 | Geniposide and baicalin medicinal composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101732334A (en) | Composition for preventing and treating cerebral ischemic apoplexy | |
| CN100528190C (en) | Oral Chinese medicinal composition for treating hypertension | |
| CN102274260A (en) | Medicinal composition of notoginseng root extract and preparation method thereof | |
| JPH07110811B2 (en) | Beef yellow heart fluid and method for producing the same | |
| CN103977010A (en) | Compound xylazine injection for dogs and preparation method thereof | |
| CN104223073B (en) | A kind of food, health products or pharmaceutical composition of sleeping | |
| Adelman et al. | Promethazine hydrochloride in surgery and obstetrics | |
| CN109044994A (en) | The new opplication of the composition of 2- baras camphor and muskone | |
| CN102743468B (en) | Traditional Chinese medicine preparation for treating headache, dizziness and concussion sequelae | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN104857001B (en) | A kind of external preparation for treating tinea pedis and preparation method thereof | |
| CN104138453B (en) | A kind of Chinese medicine preparation treating facial nerve paralysis | |
| CN101062068B (en) | Medicinal composition for treating dysmenorrhea and preparation process thereof | |
| CN106668865B (en) | For treating pharmaceutical composition, preparation and its application of cerebral ischemia | |
| Rosen et al. | The psychophysiological action of beta-erythroidin hydrochloride | |
| CN104490897B (en) | The application in preparation treatment ischemic brain injury medicine of O-(imidazole radicals) ethyl derivative of Cleistanone | |
| CN101406670B (en) | Chinese patent medicine for treating brain injury coma | |
| CN101700271B (en) | Traditional Chinese medicine preparation for treating apoplexy sequelae | |
| CN104587047A (en) | traditional Chinese medicine composition for treating cardiovascnlar and cerebrovascular diseases | |
| CN103083403A (en) | Herbal composition for lowering likelihood of stroke and methods for healing stroke patients | |
| CN101628032B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN115245553A (en) | Application of herba Euphorbiae Lathyridis extract in medicine for preventing and treating apoplexy | |
| CN110339302A (en) | It is a kind of for preventing or treating the Chinese medicine composition of alzheimer's disease | |
| CN107213154A (en) | A kind of care drug composition for being used to promote Post operation anesthesia awakening and neurotrosis to protect and application thereof | |
| CN101647875B (en) | Plant extract for treating bradycardia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100616 |